BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariosa Diagnostics, Inc. Welcomes New Board Member Michael A. Aicher


2/25/2013 8:55:02 AM

SAN JOSE, Calif., Feb. 25, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony Prenatal Test for detection of common genetic conditions, has announced the election of Michael A. Aicher to its Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

Mr. Aicher has had a very successful career in the molecular diagnostics industry having spent the last 20 years in leadership positions at National Genetics Institute (NGI), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®), and LabCorp.

As the co-founder and CEO of NGI, Mr. Aicher steered the implementation of an initial treatment model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor screening, with 15 million donations per year tested. Under various leadership positions at LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition for Mr. Aicher includes distinction as an Ernst & Young "Entrepreneur of the Year" for Emerging Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing informatics company.

"Ariosa Diagnostics is honored to welcome Michael Aicher to the board. His multiple fields of expertise in strategy and operations within molecular testing will greatly complement the existing board. We are pleased that he will share his leadership and guidance with the team at Ariosa," said Ken Song, MD, CEO of Ariosa.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
Ariosa Diagnostics
408-229-7539
jbruursema@ariosadx.com

SOURCE Ariosa Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES